You are here

Novartis

AbbVie, Pfizer, Novartis and more pledge millions in COVID-19 disaster relief

AbbVie, Pfizer, Novartis and more pledge millions in COVID-19 disaster relief

Fierce Pharma

Flag link:

Novartis cancels $1B sale of generics after antitrust concerns forced delays

Novartis cancels $1B sale of generics after antitrust concerns forced delays

Endpoints

Flag link:

No sanctions for Novartis as FDA ends review of gene therapy violations

No sanctions for Novartis as FDA ends review of gene therapy violations

BioSpace

data manipulation

Flag link:

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

Xconomy

Flag link:

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

Fierce Biotech

PCSK9 inhibitors

Flag link:

Pharma giants including Novartis collaborate on COVID-19 therapies

Pharma giants including Novartis collaborate on COVID-19 therapies

Pharmaforum

Boehringer Ingelheim

Gilead Sciences

Flag link:

Novartis escapes one set of kickback allegations, but federal charges roll on

Novartis escapes one set of kickback allegations, but federal charges roll on

Fierce Pharma

whistleblower lawsuits

Flag link:

In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug

In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug

Endpoints

non-small cell lung cancer

Flag link:

Novartis publishes long-term data from SMA gene therapy

Novartis publishes long-term data from SMA gene therapy

Pharmaforum

Flag link:

Novartis recalls immunosuppressant Sandimmune, Neoral capsules for hazardous packaging

Novartis recalls immunosuppressant Sandimmune, Neoral capsules for hazardous packaging

Fierce Pharma

product recalls

Flag link:

Novartis posts pivotal data ahead of FDA decision on $9.7B bet

Novartis posts pivotal data ahead of FDA decision on $9.7B bet

Fierce Biotech

clinical trials

Flag link:

Novartis launches $20m COVID-19 response fund

Novartis launches $20m COVID-19 response fund

PM Live

Flag link:

New sickle cell drugs priced too high, ICER says

New sickle cell drugs priced too high, ICER says

BioPharma Dive

sickle cell disease

Global Blood Therapeutics

Flag link:

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Fierce Pharma

Flag link:

FDA approves ex-Novartis drug for Cushing’s disease

FDA approves ex-Novartis drug for Cushing’s disease

Endpoints

Cushing's disease

Flag link:

Novartis taps Orionis to pursue 'historically elusive targets'

Novartis taps Orionis to pursue 'historically elusive targets'

Fierce Biotech

Orionis Biosciences

Flag link:

'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu

'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu

Fierce Pharma

occlusive vasculitis

wet age-related macular degeneration

Flag link:

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Endpoints

Pliant Therapeutics

Flag link:

Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe

Sandoz Pays $195 Million to Settle Criminal Antitrust Charges in Sweeping Federal Probe

BioSpace

Flag link:

Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review

Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review

Endpoints

Gilead Sciences

Flag link:

Pages